Yahoo Finance

Could The Market Be Wrong About Selecta Biosciences, Inc. (NASDAQ:SELB) Given Its Attractive Financial Prospects?

With its stock down 18% over the past month, it is easy to disregard Selecta Biosciences (NASDAQ:SELB). However, a closer look at its sound financials might cause you to think again. Given that ...
Yahoo Finance

Selecta Biosciences (NASDAQ:SELB) shareholders are up 22% this past week, but still in the red over the last five years

It's nice to see the Selecta Biosciences, Inc. (NASDAQ:SELB) share price up 22% in a week. But will that repair the damage for the weary investors who have owned this stock as it declined over half a ...
Seeking Alpha

Selecta surges ~20% as gout drug SEL-212 meets main goal in 2 phase 3 trials

Selecta Biosciences (NASDAQ:SELB) and Swedish Orphan Biovitrum (Sobi) (OTCPK:BIOVF) said SEL-212 met the main goals of two phase 3 trials to treat adult patients with chronic refractory gout. Gout is ...
Seeking Alpha

Murky Forecast For Selecta Biosciences' SEL-212 In Treating Chronic Refractory Gout

Selecta Biosciences is a biotech firm working on therapies for rare illnesses. SEL-212, its lead product, helps control uric acid levels in chronic refractory gout patients. SEL-212 controls serum ...
Business Wire

KKR Completes the Acquisition of ACP’s Majority Stake in Selecta

CHAM, Switzerland & LONDON & MUNICH--(BUSINESS WIRE)--KKR, a leading global investment firm, announced today the closing of the acquisition of Allianz Capital Partners’ (“ACP”) stake in the Selecta ...